The Trump administration advanced partial marijuana rescheduling in April 2026 when Acting Attorney General Todd Blanche issued a final order moving state-licensed medical cannabis and FDA-approved products containing marijuana from Schedule I to Schedule III under the Controlled Substances Act. A broader notice of proposed rulemaking for full rescheduling to Schedule III remains under review following an administrative hearing that ran from late June through mid-July 2026, with the evidentiary record now closed and the administrative law judge expected to issue a recommendation later this year. The DEA defended the proposal in post-hearing briefs, citing accepted medical use and safety under supervision in 43 jurisdictions, while opponents including Smart Approaches to Marijuana and several states filed contrary findings. A federal appeals court recently denied requests to stay the April order during related litigation. Trader consensus on near-term full rescheduling reflects the remaining steps of judge recommendation, final DEA rule, and potential court challenges before any broader change takes effect.